Browse by category

FDA approves Novo Nordisk’s oral semaglutide (Rybelsus) for CV risk reduction in T2DM adults

Novo Nordisk has received FDA approval for Rybelsus for reducing the risk of major adverse cardiovascular events (MACE) such as cardiovascular (CV) death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether they've had a prior CV event or not (primary and secondary prevention). Results of the SOUL trial reinforce the clinical profile of the semaglutide molecule, which has been studied across a variety of therapeutic areas. "Ev

SOUL trial: Oral semaglutide demonstrates a 14% reduction in risk of major adverse CV events

Headline results from the SOUL cardiovascular outcomes trial show the trial achieved its primary objective by demonstrating a...

Researchers decipher mechanism preventing the loss of brown adipose tissue activity during ageing

2 days ago

CagriSema associated with significant reduction in blood pressure and reduces the proportion of patients at risk of developing heart disease

2 days ago

Lilly and US government agree to expand access to obesity medicines

2 days ago

Browse by category

FDA approves Novo Nordisk’s oral semaglutide (Rybelsus) for CV risk reduction in T2DM adults

SOUL trial: Oral semaglutide demonstrates a 14% reduction in risk of major adverse CV events

Browse by tag

Researchers decipher mechanism preventing the loss of brown adipose tissue activity during ageing

CagriSema associated with significant reduction in blood pressure and reduces the proportion of patients at risk of developing heart disease

Lilly and US government agree to expand access to obesity medicines

Back to Top